Taken together with studies showing that humans have variants of the PM20D1 gene that associate with metabolic phenotypes (Benson et al. (Benson et al. 2019)24, our results suggest that pharmacological strategies that increase PM20D1 could be an interesting intervention to treat metabolic diseases in selected patients identified by the presence of variants that impair the expression of PM20D1. The gene discussed is PM20D1; the disease is metabolic disease.